All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine,CpG 1018
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Dynavax Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 16, 2020
Details:
BE's Phase I/II clinical trial will evaluate the safety and immunogenicity of the vaccine candidate consisting of the Receptor Binding Domain of the Spike Protein of SARS-CoV-2 at three dose levels adjuvanted with CpG 1018 plus alum, in about 360 healthy adult subjects.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tetravalent recombinant chimeric Dengue vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: DengiAll
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2020
Details:
DengiAll has illustrated the strength of Panacea Biotec’s expertise in vaccinology, research, development, and manufacturing while leveraging NIH’s ability to work on complex biological challenges to develop breakthrough technologies.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): NVX-COV2373,Matrix-M
Therapeutic Area: Infections and Infectious Diseases Product Name: NVX-COV2373
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Gavi
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 08, 2020
Details:
The collaboration will support SII to increase manufacturing capacity nowso that,once a vaccine, or vaccines,gains regulatory approvaland WHO prequalification, doses can be produced at scale for distributionto India and LMIC as part of the Gavi COVAX AMC mechanism.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 05, 2020
Details:
Zydus Cadila's plasmid DNA vaccine to prevent COVID-19, ZyCoV-D was found to be safe and well tolerated in the Phase I clinical trial. The company will now commence Phase II clinical trials
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2020
Details:
Human trial with Corona vaccine (COVAXIN) of Bharat Biotech started at PGI Rohtak.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): ZyCoV-D
Therapeutic Area: Infections and Infectious Diseases Product Name: ZyCoV-D
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2020
Details:
The Adaptive Phase I/II dose-escalation, the multi-centric study will assess the safety, tolerability and immunogenicity of the company's plasmid DNA vaccine, ZyCoV-D.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: ICMR
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 06, 2020
Details:
For covaxin, Bharat Biotech has joined with the National Institute of Virology, part of the Indian Council of Medical Research. The company is separately developing COVID-19 vaccine candidates in collaboration with Thomas Jefferson University and the University of Wisconsin.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): BBV152
Therapeutic Area: Infections and Infectious Diseases Product Name: Covaxin
Highest Development Status: Phase I/ Phase II Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 30, 2020
Details:
The SARS-CoV-2 strain was isolated in NIV, Pune and transferred to Bharat Biotech. The indigenous, inactivated vaccine developed and manufactured in Bharat Biotech’s BSL-3 (Bio-Safety Level 3) High Containment facility located in Genome Valley, Hyderabad, India.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
